Putative predictive biomarkers of ICB response include a high tumor mutational burden (TMB), an increased number of tumor-infiltrating lymphocytes (TILs), an inflammatory gene signature, positive programmed death-ligand 1 (PD-L1) expression, and MMR deficiency/microsatellite instability [165,166]. Here, CD274 is linked to neoplasm.